A 45-year-old woman comes to the clinic for complaints of abdominal pain and repeated watery stools for the past 2 days. She has a history of bowel complaints for the past 2 years consisting of periods of intermittent loose stools followed by the inability to make a bowel movement. Her past medical history is significant for diabetes controlled with metformin. She denies any abnormal oral intake, weight loss, fever, nausea/vomiting, or similar symptoms in her family. When asked to describe her stool, she reports that “it is just very watery and frequent, but no blood.” The physician prescribes a medication aimed to alleviate her symptoms. What is the most likely mechanism of action of this drug?
Q382
A 26-year-old woman is brought to the ED by her fiance with cyanosis and shortness of breath. Gradually over the last few days she has also experienced headaches, fatigue, and dizziness. Her past medical history is significant only for mild anemia attributed to menorrhagia, for which she takes an iron supplement. Per her fiance, she was recently laid-off, but is very excited about her new entrepreneurial endeavor of selling silk scarves that she dyes in their basement. She is afebrile, tachypneic, and tachycardic, and her oxygen saturation is 85% on room air, which seems high for her perceived degree of cyanosis. An arterial blood gas is drawn and the patient's blood is chocolate-colored. After a few minutes on 6 liters nasal canula, her oxygen saturation is still 85%. In addition to maintaining her airway, breathing, and circulation, what treatment should this patient also receive?
Q383
A 35-year-old woman presents to the emergency room with fever, diarrhea, and dysuria for the past day. She also complains of palpitations, poor concentration, and severe anxiety. She was diagnosed with Graves disease 6 months ago but admits that she has missed some doses of her prescribed medications in the past couple of months due to stress. Her temperature is 103°F (39°C) and pulse is 132/minute. A urine culture is obtained and grows Escherichia coli. Which of the following drugs would be most effective in treating this patient’s acute condition?
Q384
A 62-year-old man is brought to the emergency department because of a 4-hour history of abdominal pain, nausea, vomiting, and confusion. His wife reports that he had blurry vision on the way to the hospital. Two weeks ago, he lost his job and since then has been extremely worried about their financial situation and future. He has congestive heart failure and atrial fibrillation well controlled with combination medical therapy. His temperature is 36.5°C (97.7°F), pulse is 57/min and irregular, respirations are 14/min, and blood pressure is 118/63 mm Hg. The patient is oriented only to person. Serum studies show:
Na+ 138 mEq/L
Cl− 100 mEq/L
K+ 5.3 mEq/L
HCO3− 25 mEq/L
Blood urea nitrogen 14 mg/dL
Creatinine 0.9 mg/dL
An ECG shows premature ventricular beats. The drug most likely responsible for this patient's symptoms has which of the following mechanisms of action?
Q385
A 27-year-old woman comes to the physician because of a 2-month history of palpitations, diaphoresis, and a 5-kg (11-lb) weight loss. Her pulse is 101/min and blood pressure is 141/84 mm Hg. Physical examination shows a fine tremor when the fingers are outstretched. After confirmation of the diagnosis, treatment is begun with an antithyroid medication. The physician emphasizes the need for adequate contraception because of the increased risk of severe fetal malformations associated with the use of this medication, which is why its use is discouraged in the first trimester of pregnancy. Which of the following best describes the mechanism of action of this drug?
Q386
A 58-year-old man comes to the physician because of a 3-month history of intermittent pain in his right calf that occurs after walking up more than 2 flights of stairs. He reports that the pain is associated with a tingling sensation and lasts for about 10 minutes. He is otherwise healthy. He has smoked 2 packs of cigarettes daily for 30 years and drinks 1 alcoholic beverage daily. He currently takes no medications. His pulse is 78/min, and blood pressure is 180/110 mm Hg. Physical examination shows yellow plaques below the lower eyelids bilaterally, loss of hair on the distal third of the right leg, and brittle toenails on the right foot. Femoral pulses are palpable bilaterally; right popliteal and pedal pulses are absent. Which of the following is the most appropriate management to prevent future morbidity and mortality of this patient's condition?
Q387
A 55-year-old man presents to the emergency department with a 3-week history of shortness of breath. It started as exertional only, but progressed and is now present at rest. He says it's worse when he lies down; he has had a couple of episodes of waking up because of this shortness of breath with a choking sensation. He has not had any fever, cough, wheezing, or chest pain, but has noticed new swelling in his legs that has never happened before. He has also noticed that his hands and feet feel ‘weird’. Past medical history is unremarkable and social history is notable for drinking 4 vodka beverages per night for "as long as I can remember." On physical exam, his lungs have crackles up to the mid-lung fields. His bilateral lower extremities have 2+ pitting edema up to the mid-calf and he has jugular venous distension up to the angle of mandible. His bilateral hands and feet have sensory loss to pinprick and light touch with 4/5 strength on handgrip, wrist flexion and extension, ankle plantar flexion, and ankle dorsiflexion. This patient's presentation is most likely related to which of the following micronutrients?
Q388
A 60-year-old female sought a routine consultation in your clinic. She is diabetic and hypertensive. She had a history of myocardial infarction 2 years ago and is maintained on anticoagulants. When changing anticoagulants from heparin to warfarin, warfarin therapy is usually continued with heparin for the first 1–2 days. What is the rationale underlying the concurrent use of anticoagulants?
Q389
A 49-year-old woman presents to the family medicine clinic with concerns about her weight. She has been constantly gaining weight for a decade now as she has not been able to control her diet. She has tried exercising but says that she is too lazy for this method of weight loss to work. Her temperature is 37° C (98.6° F), respirations are 15/min, pulse is 67/min, and blood pressure is 122/88 mm Hg. Her BMI is 30. Her labs from her past visit show:
Fasting blood glucose: 149 mg/dL
Glycated hemoglobin (HbA1c): 9.1%
Triglycerides: 175 mg/dL
LDL-Cholesterol: 102 mg/dL
HDL-Cholesterol: 35 mg/dL
Total Cholesterol: 180 mg/dL
Serum creatinine: 1.0 mg/dL
BUN: 12 mg/dL
Serum:
Albumin: 4.2 gm/dL
Alkaline phosphatase: 150 U/L
Alanine aminotransferase: 76 U/L
Aspartate aminotransferase: 88 U/L
After discussing the long term issues that will arise if her health does not improve, she agrees to modify her lifestyle and diet. Which of the following would be the best pharmacotherapy for this patient?
Q390
A 57-year-old presents to your clinic complaining of baldness. He is overweight, has been diagnosed with BPH, and is currently taking atorvastatin for hyperlipidemia. The patient has tried several over-the-counter products for hair-loss; however, none have been effective. After discussing several options, the patient is prescribed a medication to treat his baldness that has the additional benefit of treating symptoms of BPH as well. Synthesis of which of the following compounds would be expected to decrease in response to this therapy?
Autonomic/CV Drugs US Medical PG Practice Questions and MCQs
Question 381: A 45-year-old woman comes to the clinic for complaints of abdominal pain and repeated watery stools for the past 2 days. She has a history of bowel complaints for the past 2 years consisting of periods of intermittent loose stools followed by the inability to make a bowel movement. Her past medical history is significant for diabetes controlled with metformin. She denies any abnormal oral intake, weight loss, fever, nausea/vomiting, or similar symptoms in her family. When asked to describe her stool, she reports that “it is just very watery and frequent, but no blood.” The physician prescribes a medication aimed to alleviate her symptoms. What is the most likely mechanism of action of this drug?
A. Enteric nerve stimulation
B. Substance P antagonist
C. mu-opioid receptor agonist (Correct Answer)
D. PGE1 analog
E. D2 receptor antagonist
Explanation: ***mu-opioid receptor agonist***
- The patient's history of alternating **diarrhea and constipation**, absence of alarming features like weight loss or bloody stools, and chronic nature are highly suggestive of **Irritable Bowel Syndrome (IBS)**, specifically mixed type (IBS-M) or diarrhea-predominant (IBS-D) experiencing a flare.
- Medications like **loperamide** (an over-the-counter mu-opioid receptor agonist) work by reducing **gastrointestinal motility** and increasing water absorption, effectively treating acute episodes of diarrhea in IBS.
*Enteric nerve stimulation*
- Medications that stimulate enteric nerves generally **increase gut motility**, which would worsen diarrhea rather than alleviate it.
- This mechanism is characteristic of **prokinetic agents**, which are used to treat conditions like gastroparesis, not diarrhea.
*Substance P antagonist*
- **Substance P** is a neuropeptide involved in pain transmission and inflammation, and its antagonists have been investigated for conditions like IBS with pain.
- However, they do not directly address the primary symptom of **watery stools** by altering motility or absorption.
*PGE1 analog*
- **PGE1 analogs** (e.g., misoprostol) are used to protect the gastric mucosa and can cause **diarrhea** as a side effect due to increased intestinal motility and fluid secretion.
- This mechanism would exacerbate the patient's symptoms rather than relieve them.
*D2 receptor antagonist*
- **D2 receptor antagonists** (e.g., metoclopramide) are primarily antiemetics and prokinetic agents that **increase gastric emptying** and intestinal transit.
- While they can relieve nausea and vomiting, they are not first-line treatments for diarrhea and could potentially worsen it in some cases due to increased motility.
Question 382: A 26-year-old woman is brought to the ED by her fiance with cyanosis and shortness of breath. Gradually over the last few days she has also experienced headaches, fatigue, and dizziness. Her past medical history is significant only for mild anemia attributed to menorrhagia, for which she takes an iron supplement. Per her fiance, she was recently laid-off, but is very excited about her new entrepreneurial endeavor of selling silk scarves that she dyes in their basement. She is afebrile, tachypneic, and tachycardic, and her oxygen saturation is 85% on room air, which seems high for her perceived degree of cyanosis. An arterial blood gas is drawn and the patient's blood is chocolate-colored. After a few minutes on 6 liters nasal canula, her oxygen saturation is still 85%. In addition to maintaining her airway, breathing, and circulation, what treatment should this patient also receive?
A. Deferoxamine
B. Dimercaprol
C. Methylene blue (Correct Answer)
D. Sodium bicarbonate
E. Pralidoxime
Explanation: ***Methylene blue***
- The patient's symptoms (cyanosis, shortness of breath, headaches, dizziness, fatigue) coupled with **chocolate-colored blood**, **refractory hypoxemia despite oxygen supplementation**, and a history of exposure to **aniline dyes** (from dyeing silk scarves) are highly suggestive of **methemoglobinemia**.
- **Methylene blue** acts as an electron acceptor for NADPH-methemoglobin reductase, converting ferric iron (Fe3+) in methemoglobin back to ferrous iron (Fe2+) in hemoglobin, thus restoring oxygen-carrying capacity.
*Deferoxamine*
- **Deferoxamine** is a **chelating agent** primarily used to treat **iron toxicity** or iron overload disorders like hemochromatosis.
- While the patient has mild anemia and takes iron supplements, her presentation is not consistent with acute iron poisoning.
*Dimercaprol*
- **Dimercaprol** is a chelating agent used to treat poisoning by **heavy metals** such as arsenic, mercury, and lead.
- There is no indication in the patient's history or symptoms to suggest heavy metal poisoning.
*Sodium bicarbonate*
- **Sodium bicarbonate** is primarily used to treat **metabolic acidosis**, hyperkalemia, or certain drug overdoses (e.g., tricyclic antidepressants).
- Although the patient is tachypneic, there is no direct evidence of severe acidosis warranting bicarbonate, and it does not address the underlying cause of her hypoxemia.
*Pralidoxime*
- **Pralidoxime** (2-PAM) is a **cholinesterase reactivator** used as an antidote in conjunction with atropine for **organophosphate poisoning**.
- The patient's symptoms are not consistent with cholinergic crisis from organophosphate exposure.
Question 383: A 35-year-old woman presents to the emergency room with fever, diarrhea, and dysuria for the past day. She also complains of palpitations, poor concentration, and severe anxiety. She was diagnosed with Graves disease 6 months ago but admits that she has missed some doses of her prescribed medications in the past couple of months due to stress. Her temperature is 103°F (39°C) and pulse is 132/minute. A urine culture is obtained and grows Escherichia coli. Which of the following drugs would be most effective in treating this patient’s acute condition?
A. Amiodarone
B. Methimazole
C. Lithium
D. Propranolol (Correct Answer)
E. Nitrofurantoin
Explanation: ***Propranolol***
- This patient is likely experiencing a **thyroid storm** precipitated by her UTI and medication non-adherence, given her history of Graves disease, fever, tachycardia, anxiety, and GI symptoms.
- **Propranolol**, a non-selective beta-blocker, is crucial in managing thyroid storm as it reduces the adrenergic symptoms (tachycardia, palpitations, anxiety) and also **inhibits the peripheral conversion of T4 to T3**.
*Amiodarone*
- **Amiodarone** contains a large amount of iodine, which can worsen hyperthyroidism or induce new-onset thyroid dysfunction.
- It would be contraindicated in the acute management of a thyroid storm due to its potential to further increase thyroid hormone levels.
*Methimazole*
- **Methimazole** is an antithyroid drug that blocks the synthesis of thyroid hormones; however, its effects are not immediate.
- While it is part of the long-term management of Graves disease, it would not be the most effective drug for the **acute symptoms** of a thyroid storm.
*Lithium*
- **Lithium** can inhibit the release of thyroid hormones and is sometimes used as an adjunct in treating hyperthyroidism, especially in cases of iodine sensitivity, but it is not a first-line agent.
- It has a **narrow therapeutic window** and potential for significant side effects, making it less suitable for acute stabilization compared to beta-blockers.
*Nitrofurantoin*
- **Nitrofurantoin** is an antibiotic used to treat urinary tract infections (UTIs), which this patient also has (due to *E. coli*).
- While treating the UTI is important, it will not address the **life-threatening symptoms of the thyroid storm**, such as tachycardia, fever, and anxiety.
Question 384: A 62-year-old man is brought to the emergency department because of a 4-hour history of abdominal pain, nausea, vomiting, and confusion. His wife reports that he had blurry vision on the way to the hospital. Two weeks ago, he lost his job and since then has been extremely worried about their financial situation and future. He has congestive heart failure and atrial fibrillation well controlled with combination medical therapy. His temperature is 36.5°C (97.7°F), pulse is 57/min and irregular, respirations are 14/min, and blood pressure is 118/63 mm Hg. The patient is oriented only to person. Serum studies show:
Na+ 138 mEq/L
Cl− 100 mEq/L
K+ 5.3 mEq/L
HCO3− 25 mEq/L
Blood urea nitrogen 14 mg/dL
Creatinine 0.9 mg/dL
An ECG shows premature ventricular beats. The drug most likely responsible for this patient's symptoms has which of the following mechanisms of action?
A. Blockade of aldosterone receptors
B. Blockade of beta-adrenergic receptors
C. Inhibition of Na+/K+-ATPase (Correct Answer)
D. Inhibition of Na+-K+-2Cl--cotransporters
E. Inhibition of funny channels
Explanation: ***Inhibition of Na+/K+-ATPase***
- The patient's symptoms (confusion, blurry vision, nausea, vomiting, abdominal pain, arrhythmia, hyperkalemia) are classic for **digoxin toxicity**, which occurs due to the inhibition of the **Na+/K+-ATPase pump**.
- Inhibition of this pump leads to increased intracellular calcium, enhancing cardiac contractility but also causing hyperexcitability and arrhythmias like **premature ventricular beats**.
*Blockade of aldosterone receptors*
- This mechanism is characteristic of **aldosterone antagonists** (e.g., spironolactone, eplerenone) which are often used in heart failure.
- While they can cause hyperkalemia, they typically do not cause the constellation of neurological (confusion, blurry vision) and gastrointestinal symptoms seen in this patient.
*Blockade of beta-adrenergic receptors*
- This is the mechanism of **beta-blockers** (e.g., carvedilol, metoprolol), also commonly used in heart failure and atrial fibrillation.
- Symptoms of beta-blocker overdose usually include bradycardia, hypotension, and bronchospasm, but not the prominent GI or blurry vision symptoms seen here.
*Inhibition of Na+-K+-2Cl--cotransporters*
- This mechanism belongs to **loop diuretics** (e.g., furosemide), often used in congestive heart failure.
- Loop diuretics primarily cause electrolyte imbalances such as hypokalemia and hypomagnesemia, and volume depletion, which does not match the patient's presentation of hyperkalemia and specific digoxin toxicity symptoms.
*Inhibition of funny channels*
- This is the mechanism of action of **ivabradine**, a selective inhibitor of the I_f current in the sinoatrial node, used to reduce heart rate in heart failure.
- While it can cause bradycardia, it is not associated with the severe GI distress, neurological symptoms, or hyperkalemia observed in this patient.
Question 385: A 27-year-old woman comes to the physician because of a 2-month history of palpitations, diaphoresis, and a 5-kg (11-lb) weight loss. Her pulse is 101/min and blood pressure is 141/84 mm Hg. Physical examination shows a fine tremor when the fingers are outstretched. After confirmation of the diagnosis, treatment is begun with an antithyroid medication. The physician emphasizes the need for adequate contraception because of the increased risk of severe fetal malformations associated with the use of this medication, which is why its use is discouraged in the first trimester of pregnancy. Which of the following best describes the mechanism of action of this drug?
A. Inhibition of thyroid hormone release
B. Inhibition of peripheral conversion of T4 to T3
C. Decreased iodide uptake by follicular cells
D. Suppression of thyroid-stimulating hormone release
E. Inhibition of iodide ion oxidation (Correct Answer)
Explanation: ***Inhibition of iodide ion oxidation***
- The patient's symptoms (palpitations, diaphoresis, weight loss, tremor, tachycardia, hypertension) are classic for **hyperthyroidism**, likely **Graves' disease**.
- The antithyroid drug described, which is contraindicated in the first trimester due to teratogenicity, is **methimazole**. Methimazole (and propylthiouracil) primarily inhibits **thyroid peroxidase**, thereby preventing the **oxidation of iodide** and its subsequent organification into tyrosine residues on thyroglobulin, blocking thyroid hormone synthesis.
*Inhibition of thyroid hormone release*
- This mechanism is characteristic of **iodides** (e.g., Lugol's solution, potassium iodide), which acutely inhibit the release of pre-formed thyroid hormones from the thyroid gland.
- While iodides can be used for rapid control of hyperthyroidism (e.g., before surgery or in thyroid storm), they are not the primary long-term antithyroid medications and do not carry the specific first-trimester teratogenicity risk described for PTU/methimazole.
*Inhibition of peripheral conversion of T4 to T3*
- This mechanism is primarily associated with **propylthiouracil (PTU)** (in addition to inhibiting thyroid hormone synthesis) and **beta-blockers** (like propranolol), as well as **glucocorticoids** and **amiodarone**.
- While PTU also inhibits iodide oxidation, its unique ability to inhibit peripheral T4 to T3 conversion makes it the preferred antithyroid drug in the **first trimester of pregnancy** due to a lower teratogenic risk compared to methimazole, directly contrasting the drug described in the question.
*Decreased iodide uptake by follicular cells*
- This is the mechanism of action of **perchlorate** and **thiocyanate**, which are competitive inhibitors of the **sodium-iodide symporter (NIS)**, blocking iodide transport into follicular cells.
- These agents are rarely used clinically due to toxicity concerns and are not the first-line antithyroid drugs with the described teratogenic profile.
*Suppression of thyroid-stimulating hormone release*
- **TSH release** from the pituitary is primarily suppressed by **negative feedback** from high levels of circulating thyroid hormones (T3 and T4), or by direct intervention with agents like **somatostatin analogs** (e.g., octreotide) in rare cases of TSH-producing pituitary adenomas.
- Antithyroid drugs do not directly suppress TSH release; rather, by reducing thyroid hormone levels, they would eventually lead to an *increase* in TSH secretion if hyperthyroidism were adequately treated and feedback restored.
Question 386: A 58-year-old man comes to the physician because of a 3-month history of intermittent pain in his right calf that occurs after walking up more than 2 flights of stairs. He reports that the pain is associated with a tingling sensation and lasts for about 10 minutes. He is otherwise healthy. He has smoked 2 packs of cigarettes daily for 30 years and drinks 1 alcoholic beverage daily. He currently takes no medications. His pulse is 78/min, and blood pressure is 180/110 mm Hg. Physical examination shows yellow plaques below the lower eyelids bilaterally, loss of hair on the distal third of the right leg, and brittle toenails on the right foot. Femoral pulses are palpable bilaterally; right popliteal and pedal pulses are absent. Which of the following is the most appropriate management to prevent future morbidity and mortality of this patient's condition?
A. Clopidogrel therapy (Correct Answer)
B. Percutaneous transluminal angioplasty
C. Cilostazol therapy
D. Graded exercise therapy
E. Pentoxifylline therapy
Explanation: ***Clopidogrel therapy***
- **Antiplatelet therapy** with clopidogrel (or aspirin) is crucial for **preventing future morbidity and mortality** in PAD patients by reducing the risk of **myocardial infarction**, stroke, and cardiovascular death.
- PAD is a manifestation of systemic atherosclerosis, and these patients have significantly elevated cardiovascular risk. Antiplatelet therapy addresses this systemic risk and is a cornerstone of medical management.
- Current guidelines (ACC/AHA) strongly recommend antiplatelet therapy for all patients with symptomatic PAD to reduce adverse cardiovascular events.
*Graded exercise therapy*
- **Graded exercise therapy** is highly effective for improving walking distance and reducing claudication symptoms by promoting collateral circulation and improving endothelial function.
- While exercise is essential for symptom management and quality of life, it is **not the primary intervention for preventing mortality** in PAD patients, which is what this question specifically asks about.
- Exercise should be recommended alongside antiplatelet therapy and risk factor modification.
*Pentoxifylline therapy*
- **Pentoxifylline** may improve red blood cell flexibility and microcirculation, but it has shown limited efficacy for symptom relief and **no proven benefit for reducing cardiovascular mortality**.
- Its use is generally reserved for patients who cannot tolerate other treatments.
*Percutaneous transluminal angioplasty*
- **Revascularization** (PTA or surgical bypass) is typically reserved for patients with severe, lifestyle-limiting claudication unresponsive to medical therapy, or for critical limb ischemia.
- This patient has intermittent claudication with moderate symptoms, making conservative medical management more appropriate initially.
- Revascularization improves symptoms but does not reduce mortality compared to medical therapy alone.
*Cilostazol therapy*
- **Cilostazol** is a phosphodiesterase-3 inhibitor that improves walking distance and claudication symptoms through vasodilation and antiplatelet effects.
- While effective for symptomatic relief, it does **not reduce cardiovascular mortality** and has a contraindication in heart failure patients.
- It is used as an adjunct for symptom management, not as primary prevention of morbidity and mortality.
Question 387: A 55-year-old man presents to the emergency department with a 3-week history of shortness of breath. It started as exertional only, but progressed and is now present at rest. He says it's worse when he lies down; he has had a couple of episodes of waking up because of this shortness of breath with a choking sensation. He has not had any fever, cough, wheezing, or chest pain, but has noticed new swelling in his legs that has never happened before. He has also noticed that his hands and feet feel ‘weird’. Past medical history is unremarkable and social history is notable for drinking 4 vodka beverages per night for "as long as I can remember." On physical exam, his lungs have crackles up to the mid-lung fields. His bilateral lower extremities have 2+ pitting edema up to the mid-calf and he has jugular venous distension up to the angle of mandible. His bilateral hands and feet have sensory loss to pinprick and light touch with 4/5 strength on handgrip, wrist flexion and extension, ankle plantar flexion, and ankle dorsiflexion. This patient's presentation is most likely related to which of the following micronutrients?
A. Vitamin B3
B. Vitamin B12
C. Vitamin B1 (Correct Answer)
D. Vitamin B2
E. Vitamin A
Explanation: ***Vitamin B1***
- This patient's symptoms, including **shortness of breath**, **orthopnea**, paroxysmal nocturnal dyspnea (PND), bilateral lower extremity **edema**, crackles, and jugular venous distension, are consistent with **heart failure**, a hallmark of **wet beriberi** (B1 deficiency).
- The **neurological symptoms** (sensory loss, 4/5 strength) affecting hands and feet suggest **peripheral neuropathy**, characteristic of **dry beriberi**. Combined with a history of **chronic alcohol abuse**, which impairs thiamine absorption and leads to malnutrition, vitamin B1 deficiency is the most likely cause.
*Vitamin B3*
- Deficiency of vitamin B3 (**niacin**), known as **pellagra**, typically presents with the "3 Ds": **dermatitis**, **diarrhea**, and **dementia**.
- While chronic alcohol use is a risk factor for pellagra, the patient's primary symptoms of heart failure and peripheral neuropathy are not characteristic of niacin deficiency.
*Vitamin B12*
- **Vitamin B12 deficiency** can cause **megaloblastic anemia** and neurological symptoms, including **peripheral neuropathy**, sensory disturbances, and subacute combined degeneration of the spinal cord.
- However, the prominent signs of **heart failure** (shortness of breath, orthopnea, edema, JVD) are not typical features of B12 deficiency.
*Vitamin B2*
- **Vitamin B2 deficiency** (riboflavin) is characterized by symptoms such as **cheilosis** (cracks at the corners of the mouth), **glossitis** (inflammation of the tongue), and **seborrheic dermatitis**.
- It does not typically cause heart failure or significant peripheral neuropathy as the primary presenting symptoms.
*Vitamin A*
- **Vitamin A deficiency** is primarily associated with **ocular symptoms** like **night blindness** and xerophthalmia, as well as impaired immune function and hyperkeratosis.
- Heart failure and peripheral neuropathy are not recognized manifestations of vitamin A deficiency.
Question 388: A 60-year-old female sought a routine consultation in your clinic. She is diabetic and hypertensive. She had a history of myocardial infarction 2 years ago and is maintained on anticoagulants. When changing anticoagulants from heparin to warfarin, warfarin therapy is usually continued with heparin for the first 1–2 days. What is the rationale underlying the concurrent use of anticoagulants?
A. Warfarin is metabolized slowly, thus leading to a delay in anticoagulation if heparin is not also administered.
B. To compensate for the initial prothrombotic property of warfarin (Correct Answer)
C. To prevent bleeding because heparin partially counteracts the warfarin hemorrhagic property
D. Heparin decreases the clearance of warfarin, thus achieving a greater plasma drug concentration of warfarin.
E. To achieve supraoptimal anticoagulation during critical periods of illness because warfarin and heparin have synergistic effects
Explanation: ***To compensate for the initial prothrombotic property of warfarin***
- Warfarin inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and also **protein C** and **protein S**, which are natural anticoagulants.
- Protein C has a shorter half-life than the procoagulant factors, leading to a temporary **hypercoagulable state** or **prothrombotic effect** initially, which requires bridging with heparin.
*Warfarin is metabolized slowly, thus leading to a delay in anticoagulation if heparin is not also administered.*
- While warfarin's full anticoagulant effect is delayed due to the half-lives of existing clotting factors, the primary reason for co-administration is to cover the initial **prothrombotic phase** from protein C depletion.
- The slow metabolism is related to the time it takes for therapeutic effect, not directly the cause of initial hypercoagulation.
*To prevent bleeding because heparin partially counteracts the warfarin hemorrhagic property*
- This statement is incorrect; co-administration of heparin and warfarin increases the risk of bleeding, as both are anticoagulants.
- The purpose of concurrent use is to maintain a therapeutic anticoagulant effect and prevent thrombosis, not to counteract bleeding.
*Heparin decreases the clearance of warfarin, thus achieving a greater plasma drug concentration of warfarin.*
- Heparin does not significantly interact with warfarin's metabolism or clearance to increase its plasma concentration.
- Their mechanisms of action are distinct: heparin potentiates antithrombin, while warfarin inhibits vitamin K-dependent factor synthesis.
*To achieve supraoptimal anticoagulation during critical periods of illness because warfarin and heparin have synergistic effects*
- The goal is to achieve **therapeutic anticoagulation**, not "supraoptimal" levels, which would greatly increase bleeding risk.
- While they have additive anticoagulant effects, the "synergistic" concept in this context is less accurate than addressing the initial prothrombotic state.
Question 389: A 49-year-old woman presents to the family medicine clinic with concerns about her weight. She has been constantly gaining weight for a decade now as she has not been able to control her diet. She has tried exercising but says that she is too lazy for this method of weight loss to work. Her temperature is 37° C (98.6° F), respirations are 15/min, pulse is 67/min, and blood pressure is 122/88 mm Hg. Her BMI is 30. Her labs from her past visit show:
Fasting blood glucose: 149 mg/dL
Glycated hemoglobin (HbA1c): 9.1%
Triglycerides: 175 mg/dL
LDL-Cholesterol: 102 mg/dL
HDL-Cholesterol: 35 mg/dL
Total Cholesterol: 180 mg/dL
Serum creatinine: 1.0 mg/dL
BUN: 12 mg/dL
Serum:
Albumin: 4.2 gm/dL
Alkaline phosphatase: 150 U/L
Alanine aminotransferase: 76 U/L
Aspartate aminotransferase: 88 U/L
After discussing the long term issues that will arise if her health does not improve, she agrees to modify her lifestyle and diet. Which of the following would be the best pharmacotherapy for this patient?
A. Insulin
B. Metformin (Correct Answer)
C. Dietary modification alone
D. Sitagliptin
E. Glipizide
Explanation: ***Metformin***
- This patient has newly diagnosed **type 2 diabetes mellitus** (Fasting blood glucose 149 mg/dL, HbA1c 9.1%) in the setting of obesity (BMI 30). **Metformin** is the **first-line pharmacotherapy** for type 2 diabetes due to its efficacy, favorable safety profile, and potential for weight neutrality or modest weight loss.
- Metformin works by **decreasing hepatic glucose production**, decreasing intestinal glucose absorption, and increasing insulin sensitivity.
*Insulin*
- While insulin is highly effective in lowering blood glucose, it is typically reserved for patients with **very high HbA1c** (often >10%), **symptomatic hyperglycemia**, or those who have failed oral pharmacotherapy, it can also cause **weight gain**.
- Initiating insulin as first-line therapy can be overly aggressive and may lead to **hypoglycemia** in patients who can respond to oral agents.
*Dietary modification alone*
- Although **lifestyle changes** (diet and exercise) are crucial and can be remarkably effective, this patient's **HbA1c of 9.1%** indicates that **monotherapy with diet and exercise alone is insufficient** to achieve glycemic control.
- Pharmacotherapy is generally recommended for HbA1c levels **above 7.5%**, even with a commitment to lifestyle changes.
*Sitagliptin*
- **Sitagliptin** is a **DPP-4 inhibitor** that increases insulin secretion and decreases glucagon secretion in a glucose-dependent manner.
- It is often considered a **second-line agent** or an add-on therapy, as its HbA1c-lowering effect is generally less potent than metformin.
*Glipizide*
- **Glipizide** is a **sulfonylurea** that works by stimulating insulin release from pancreatic beta cells.
- It can cause **weight gain** and has a significant risk of **hypoglycemia**, making it a less favorable first-line agent, especially in an obese patient, compared to metformin.
Question 390: A 57-year-old presents to your clinic complaining of baldness. He is overweight, has been diagnosed with BPH, and is currently taking atorvastatin for hyperlipidemia. The patient has tried several over-the-counter products for hair-loss; however, none have been effective. After discussing several options, the patient is prescribed a medication to treat his baldness that has the additional benefit of treating symptoms of BPH as well. Synthesis of which of the following compounds would be expected to decrease in response to this therapy?
A. Testosterone
B. FSH
C. LH
D. GnRH
E. DHT (Correct Answer)
Explanation: ***DHT***
- The medication described is likely **finasteride**, a **5-alpha-reductase inhibitor**. This enzyme converts **testosterone** to **dihydrotestosterone (DHT)**.
- Decreased DHT levels are beneficial for treating both **androgenetic alopecia (baldness)** and **benign prostatic hyperplasia (BPH)** due to its potent androgenic effects on hair follicles and prostate growth.
*Testosterone*
- While finasteride inhibits the conversion of testosterone to DHT, it does not directly decrease testosterone synthesis. In fact, **testosterone levels may slightly increase** as its conversion to DHT is blocked.
- Testosterone itself is not the primary androgen responsible for male pattern baldness or BPH; it's its more potent metabolite, DHT.
*FSH*
- **Follicle-stimulating hormone (FSH)** is a gonadotropin released from the anterior pituitary that stimulates sperm production and ovarian follicle development.
- The medication prescribed does not directly affect FSH synthesis or release; its action is peripheral, affecting androgen metabolism.
*LH*
- **Luteinizing hormone (LH)** is another gonadotropin that stimulates testosterone production in Leydig cells.
- The drug's mechanism of action is local inhibition of an enzyme, not a central regulation of pituitary hormones like LH.
*GnRH*
- **Gonadotropin-releasing hormone (GnRH)** is released from the hypothalamus and stimulates the anterior pituitary to release FSH and LH.
- This therapy specifically targets the conversion of an androgen and does not impact the hypothalamic-pituitary-gonadal axis at the level of GnRH.